Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Oramed Pharmaceuticals Announces Reverse Stock Split

January 22, 2013

JERUSALEM, January 22, 2013 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (OTCQB:ORMP) (http://www.oramed.com), a developer of
oral drug delivery systems, announced today that its previously announced one for twelve
reverse stock split has become effective. As of the open of business on January 23, 2013,
the shares of Oramed will be trading on a reverse split-adjusted basis on the OTCQB Market
under the symbol “ORMPD,” which replaces the previous symbol “ORMP” for the next 20
business days. Oramed effected the reverse stock split in order to help it meet the
qualifications for listing its shares on the Nasdaq Capital Market.

The reverse split reduces the number of shares of Oramed’s authorized shares of common
stock from approximately 200,000,000 to approximately 16,666,667 and outstanding shares
common stock from approximately 86,505,020 to approximately 7,209,652. The exercise price
and the number of shares of common stock issuable under Oramed’s outstanding warrants and
options have been proportionately adjusted to reflect the reverse stock split. Fractional
shares created as a result of the stock split will be rounded up to the next whole share.

“We are taking steps to move our company forward on many fronts and this reverse stock
split puts us closer to our goal of up-listing to a major market in the U.S.,” commented
Oramed CEO, Nadav Kidron.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 30 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801)
currently approaching FDA-approved Phase 2 clinical trials, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 1b/2a trials. The
company’s corporate and R&D headquarters are based in Jerusalem.

The company’s fact sheet can be viewed here
[http://oramed.com/ufiles/Oramed-fact-sheet-Oct-2012.pdf ].

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements.
For example, we are using forward-looking statements when we discuss how the reverse stock
split puts us closer to our goal of up-listing to a major market in the U.S. These
forward-looking statements are based on the current expectations of the management of
Oramed only, and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to difficulties or delays in
obtaining approval for the listing of our shares on Nasdaq, Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed description of the
risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from
time to time with the Securities and Exchange Commission.

        Company Contact:
        Oramed Pharmaceuticals
        Aviva Sherman
        Cell: +972-54-792-4438
        Office: +972-2-566-0001
        Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


Source: PR Newswire